EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

TPS47 - Biologicals 2

Saturday 01 Jun, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
A possible integrated mind-body approach to CSU treatment
ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomised, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps
Comparable Efficacy and Pharmacodynamic Results of CT-P39 to Reference Omalizumab in Patients with Chronic Spontaneous Urticaria
Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody
Dupilumab: real-life experience of effectiveness, safety and impact on type 2 and non-type 2 comorbidity in atopic dermatitis in paediatric, adolescent and adult patients n Argentina: 4-year review
Efficacy of dupilumab in atopic dermatitis with prurigo : a real-life study
LAD2 Mast Cell Activation Test in Chronic Spontaneous Urticaria
Optimizing Omalizumab Therapy in Chronic Urticaria: Tailored Approaches for Weaning and Sustained Remission
Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
Successful treatment of lichen amyloidosis with dupilumab treatment: a case report
Urticaria Outpatient Clinic: one year experience of a Portuguese center
VEXAS patient successfully treated with canakinumab

Chairs

Speakers